Literature DB >> 28414572

Molecular Characterization of Fluoroquinolone-Resistant Haemophilus parainfluenzae Clinical Isolates in Spain.

Inmaculada López-Hernández1, Jesús Machuca1, Paula Díaz de Alba1, Carolina Sarvisé2, Frederic Gómez2, José Manuel Rodríguez-Martínez3, Alvaro Pascual1,3.   

Abstract

OBJECTIVE: The objective was to characterize a group of clinical isolates of fluoroquinolone-resistant Haemophilus parainfluenzae collected in Northern Spain (March-December 2014).
METHODS: Twelve clinical isolates of H. parainfluenzae were studied by performing antimicrobial susceptibility testing and PCR amplification and nucleotide sequencing of the QRDR (quinolone resistance-determining region) of gyrA, parC, gyrB, and parE genes. Screening for plasmid-mediated quinolone resistance (PMQR) was also studied. Pulsed-field gel electrophoresis (PFGE) was used for molecular typing.
RESULTS: Antimicrobial susceptibility testing showed that all the isolates were resistant to the fluoroquinolones tested (ciprofloxacin, levofloxacin, norfloxacin, and moxifloxacin). Analysis of the QRDR demonstrated that all the isolates presented mutations in gyrA and parC. A Glu88Lys substitution in ParC is reported for the first time in H. parainfluenzae. No PMQR gene was detected. PFGE results showed that isolates were not clonally related.
CONCLUSION: Multiple H. parainfluenzae fluoroquinolone-resistant isolates grouped in the same area in a short period of time showed diverse substitutions in QRDR of gyrA/parC and were not clonally related, indicating individual emergence. In addition, we described the first report of Glu88Lys substitution in ParC.

Entities:  

Keywords:  H. parainfluenzae; Spain; fluoroquinolones; resistance

Mesh:

Substances:

Year:  2017        PMID: 28414572     DOI: 10.1089/mdr.2016.0186

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  2 in total

1.  Emergence of multidrug resistance among Haemophilus parainfluenzae from respiratory and urogenital samples in Barcelona, Spain.

Authors:  Yanik Sierra; Aida González-Díaz; Fe Tubau; Arkaitz Imaz; Meritxell Cubero; Jordi Càmara; Josefina Ayats; Sara Martí; Carmen Ardanuy
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-12-11       Impact factor: 3.267

2.  Efficacy of Delafloxacin versus Moxifloxacin against Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Microbiology Results from the Delafloxacin Phase 3 CABP Trial.

Authors:  Sandra McCurdy; Kara Keedy; Laura Lawrence; Ashley Nenninger; Amanda Sheets; Megan Quintas; Sue Cammarata
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.